Business Context and Reporting Period
Company: IRIDEX Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 3, 2004
Business Overview: IRIDEX develops, manufactures, and markets medical devices for ophthalmology and dermatology. The company operates in two reportable segments: Ophthalmology Medical Devices and Dermatology Medical Devices. As of May 14, 2004, there were 7,208,635 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q1 2004 | Q1 2003 |
|---|---|---|
| Sales | $7,392 | $7,226 |
| Gross Profit | $3,215 | $3,238 |
| Gross Margin | 43.5% | 44.8% |
| Operating Expenses | $3,300 | $3,414 |
| Net Loss | $(17) | $(82) |
| Net Loss Per Share (Basic/Diluted) | $(0.00) | $(0.01) |
| Cash and Cash Equivalents | $9,477 | $10,541 (Jan 3, 2004) |
| Available-for-Sale Securities | $7,438 | $5,751 (Jan 3, 2004) |
| Total Liquidity | $16.9 million | N/A |
| Debt | $0 (No borrowings on $4M line of credit) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total sales increased 2.3% to $7.39 million, driven primarily by a 9.1% increase in Ophthalmology sales ($6.24 million). International ophthalmology sales rose 25.0%.
- Dermatology Decline: Dermatology sales decreased 23.5% to $1.15 million, attributed to increased competition and a decline in unit sales of the DioLite laser.
- Profitability: Net loss improved significantly to $17,000 from $82,000 in the prior year. Operating loss narrowed to $85,000 from $176,000.
- Expense Management: Sales, General, and Administrative (SG&A) expenses decreased 11.0% due to open sales positions and reduced marketing spend. Research and Development (R&D) expenses increased 16.5% due to project spending.
- Cash Flow: Operating cash flow turned positive at $7,000, compared to $1.82 million in the prior year, largely due to a decrease in accounts receivable and inventory levels.
Guidance, Outlook, and Risks
Management Commentary: Management expects gross profit margins to fluctuate due to product mix, pricing, and geographic sales distribution. The company is focusing on inventory reduction and cost mitigation to offset downward pressure on average selling prices.
Outlook: The company believes current cash, securities, and its $4 million credit facility are sufficient to meet requirements for the next 12 months. Future success depends on the market acceptance of new products (e.g., 50 micron slit lamp adaptor, EndoProbe) and the outcome of the TTT4CNV clinical trial for wet AMD, with results expected in Q4 2004.
Key Risks and Contingencies:
- Reimbursement Uncertainty: Domestic sales of the OcuLight SLx laser are limited by varying Medicare reimbursement policies for AMD procedures.
- Collaboration Risks: Success with Miravant Medical Technologies depends on the FDA approval of SnET2-PDT; Miravant's Phase III trial previously failed to meet primary efficacy endpoints.
- Supply Chain: Reliance on sole or limited source suppliers for critical components (optics, laser diodes) poses a risk of production delays.
- Accounting Changes: Potential future adoption of fair value accounting for stock-based compensation (FASB Exposure Draft) could significantly increase reported expenses.
Investor Verification Checklist
- Cash Position: Verify the $16.9 million liquidity position (cash + securities) against the $4 million unsecured line of credit expiring in October 2004.
- Reimbursement Status: Monitor updates on CMS and local carrier reimbursement policies for TTT procedures, which directly impact Ophthalmology sales.
- Clinical Trial Results: Track the release of the TTT4CNV clinical trial results expected in Q4 2004, as a favorable outcome is critical for future growth.
- Stock-Based Compensation: Review the pro forma net loss of $(161,000) if fair value accounting were applied, indicating potential future earnings pressure.
- Inventory Levels: Confirm the effectiveness of the inventory reduction program, as inventory reserves contributed to a 1.2% decrease in gross margin.